InvestorsHub Logo
Post# of 175422
Next 10
Followers 23
Posts 4384
Boards Moderated 0
Alias Born 07/15/2012

Re: None

Monday, 02/05/2024 7:45:24 PM

Monday, February 05, 2024 7:45:24 PM

Post# of 175422
RadioGel™ – compared to current brachytherapy treatment technology
Next-Generation Breakthrough cancer treatment
Based upon its studies and analyses, or general application of experience with current brachytherapy devices and Yttrium-90, Vivos believes that its brachytherapy products are likely to offer the following benefits, among others, for patients and medical professionals:



• Maximizing Therapeutic Index: The short-range beta particles emitted by Y-90 deliver radiation energy within a tight range. This enables radiation to be selectively delivered to target tissues while minimizing radiation dose to nearby normal tissues. High therapeutic indices imply that more radiation energy may be imparted to target tissues, with less radiation reaching adjacent normal tissues.



• Half Life: Y-90 has a half-life of just 2.7 days. Many traditional brachytherapy products use isotopes with longer half-lives such as 9.7 days for cesium-131, and sixty days for iodine-125.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RDGL News